Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use

a technology of peptide agents and peptide sources, which is applied in the direction of peptide sources, angiogenin, growth hormones, etc., can solve the problems of pathological impairment, poor vascular development, rapid and excessive angiogenesis accompanies the growth of placenta and solid tumors,
US20080090750A1Inactive Publication Date: 2008-04-17RGT UNIV OF CALIFORNIA
5 Cites 2 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
RGT UNIV OF CALIFORNIA
Publication Date
2008-04-17
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of the priority date of and is a continuation of U.S. application Ser. No. 09 / 076,675, filed May 12, 1998, which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application No. 60 / 046,394, filed May 13, 1997.BACKGROUND OF THE INVENTION

[0002] A growing number of serious, debilitating and often fatal diseases are associated with angiogenesis. These diseases are cumulatively called angiogenic diseases. Under normal physiological conditions, angiogenesis in mammals is endogenously controlled throughout the lifetime and neovascularization rarely occurs except during embryonic development, the reproductive cycle, and wound healing.

[0003] Examples of the pathological conditions leading to development of angiogenic diseases are, among others, arthritis, rheumatoid arthritis, atherosclerotic plaques, corneal graft neovascularization, wound healing, hypertrophic or keloid scars, proliferative retinopathy, diabetic retinopathy, macular de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More